Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation
Equity Bottom-Up
161 Views, 07 Dec 2021 09:00
EXECUTIVE SUMMARY
We analyzed the business performance and short-term catalyst for Sino Biopharmaceutical (1177 HK), and investors could decide whether to take advantage of it or not.
We also analyzed the concerns about the Company as well as our insights on the valuation of biopharmaceutical companies.
Based on our analysis, we are conservative about the Company’s outlook at the current stage.